Searchable abstracts of presentations at key conferences in endocrinology

ea0065p164 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Case report on Immunotherapy mediated hypocortisolemia

Varghese Jeanny , Humphriss David

63 year old gentleman, admitted in Nov 2018. Feeling generally unwell, decreased appetite, lethargy and poor mobility. Known lung cancer (diagnosed January 2018) On Immunotherapy last received in October 2018CT scan (September 2018) after 4 cycles of Pembrolizumab–excellent response to treatment. Routine blood tests were normal apart from a raised CRP at 551 and white cell count. A random cortisol level was done and found to be low at 135. Blood, urine, sputum and stool c...

ea0049gp65 | Developmental & Protein Endocrinology | ECE2017

3-year safety and efficacy Update of the VERTICAL & VISTA trials of somavaratan (VRS-317), a long-acting rhGH, in children with Growth Hormone Deficiency (GHD)

Miller Bradley S. , Moore Wayne V. , Fechner Patricia Y. , Van Meter Quentin L. , Fuqua John S. , Ng David , Humphriss Eric , Charlton R. William , Bright George M.

Requirement for daily rhGH injections is a treatment burden that can compromise adherence and efficacy in patients with GHD. Somavaratan is a novel long-acting rhGH fusion protein in clinical development for pediatric and adult GHD. In a multicenter, randomized Phase 1b/2a study, somavaratan significantly improved height velocity (HV) and IGF-I in pre-pubertal children with GHD. Preliminary efficacy and safety in subjects who have completed 3 years of somavaratan treatment are...